Inhibition of proliferation of human small cell lung cancer cells expressing an autocrine system for gastrin releasing peptide by antisense oligodeoxynucleotides to gastrin releasing peptide receptor

Lung Cancer

Volumn 36, Issue 3, 2002, Pages 235-242

  Langer, Daniel A ^a,b   Kautzman, Donna ^a   Kane, Madeleine A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Antisense oligodeoxynucleotides; Bombesin like peptides; Lung cancer

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; MESSENGER RNA; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; SPECTROPHOTOMETRY;

CARCINOMA, SMALL CELL; CELL DIVISION; GASTRIN-RELEASING PEPTIDE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; RECEPTORS, BOMBESIN; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0036253370     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00490-1     Document Type: Article

References (42)

1. Epidemiology of lung cancer
2. Non-small cell lung cancer
3. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
4. Inhibitors of bombesin-stimulated intracellular signals: Interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma
5. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells
6. CDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor
7. BRS-3: A novel bombesin-like peptide receptor selectively expressed in testis and lung cancer cells
8. Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R)
9. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells
10. Bombesin-like peptide receptor expression by human bronchial epithelial cells
11. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells
12. Neuropeptide stimulation of calcium flux in human lung cancer cells
13. [D-Arg1,D-Phe5,D-Trp7,9,Leu11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro
14. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma
15. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer
16. Nucleic acid therapeutics: State of the art and future prospects
17. Antisense comes of age
18. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
19. A Phase 1 trial H-ras antisense oligonucleotide ISIS 2503, administered as a continuous intravenous infusion in patients with advanced cancer
20. A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras, administered by a 24-hour (hr) weekly infusion to patients (pts) with advanced cancer
21. A phase I trial of c-Raf kinase antisense oligonuclotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
22. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha in patients with advanced cancer
23. Phase I study of an antisense oliognuclotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
24. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM 231) targeting the Type I protein kinase by two-hour infusions in patients with refractory solid tumors
25. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
26. Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes
27. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor
28. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor
29. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis
30. In vivo studies with antisense oligonucleotides
31. Expression of bombesin-receptor subtypes and their differential regulation of colonic smooth muscle contraction
32. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung
33. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes
34. A colorimetric method for determining cell growth
35. Improved non-radioactive assay to measure cellular proliferation or toxicity: The CellTiter 96® Aqueous One Solution Cell Proliferation Assay
36. Nonconstitutive expression of the gastrin releasing peptide autocrine growth system in human small cell lung carcinoma NCI-H345 cells
37. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo
38. Characterization of tumor-associated neural cell adhesion molecule in human serum
39. Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer
40. Effects of different immunolabeling techniques on the detection of small-cell lung cancer cells in bone marrow
41. Bombesin treatment enhances vasopressin receptors in Swiss 3T3 cells
42. Autocrine growth loops dependent on peptidyl α-amidating enzyme as targets for novel tumor cell growth inhibitors